Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology
To determine if tumor cell density and percentage of Gleason pattern within an outlined volumetric tumor region of interest (TROI) on whole-mount pathology (WMP) correlate with apparent diffusion coefficient (ADC) values on corresponding TROIs outlined on pre-operative MRI.
Men with biopsy-proven prostate adenocarcinoma undergoing multiparametric MRI (mpMRI) prior to prostatectomy were consented to this prospective study. WMP and mpMRI images were viewed using 3D Slicer and each TROI from WMP was contoured on the high b-value ADC maps (b0, 1400). For each TROI outlined on WMP, TCD (tumor cell density) and the percentage of Gleason pattern 3, 4, and 5 were recorded. The ADCmean, ADC10th percentile, ADC90th percentile, and ADCratio were also calculated in each case from the ADC maps using 3D Slicer.
Nineteen patients with 21 tumors were included in this study. ADCmean values for TROIs were 944.8 ± 327.4 vs. 1329.9 ± 201.6 mm2/s for adjacent non-neoplastic prostate tissue (p < 0.001). ADCmean, ADC10th percentile, and ADCratio values for higher grade tumors were lower than those of lower grade tumors (mean 809.71 and 1176.34 mm2/s, p = 0.014; 10th percentile 613.83 and 1018.14 mm2/s, p = 0.009; ratio 0.60 and 0.94, p = 0.005). TCD and ADCmean (ρ = −0.61, p = 0.005) and TCD and ADC10th percentile (ρ = −0.56, p = 0.01) were negatively correlated. No correlation was observed between percentage of Gleason pattern and ADC values.
DWI MRI can characterize focal prostate cancer using ADCratio, ADC10th percentile, and ADCmean, which correlate with pathological tumor cell density.
KeywordsProstate cancer MRI ADC DWI Gleason pattern
The authors thank Louise Greenberg, M.Ed. for coordination of this study and Nina Geller Ph.D. for editing assistance.
Grant funding was provided by U01CA151261 (FMF, AF), U24CA180918 (AF), R25CA89017 (DIG), P41EB015898 (CT, FF, AF), and DPH403516 (EH).
Compliance with Ethical Standards
Conflict of Interest
The study was HIPAA compliant and approved by the Institutional Review Board. Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Cancer Facts & Figures (2016) American Cancer Society, AtlantaGoogle Scholar
- 10.Turkbey B, Brown AM, Sankineni S, et al. (2015) Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin 40(7):2557–2565Google Scholar
- 29.Fennessy FM, Fedorov A, Penzkofer T, et al. (2015) Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging 33(7):886–894CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Vargas HA, Hötker AM, Goldman DA, et al. (2015) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol . doi: 10.1007/s00330-015-4015-6 Google Scholar